1. Mangiferin Attenuates Myocardial Ischemia-Reperfusion Injury via MAPK/Nrf-2/HO-1/NF- κ B In Vitro and In Vivo .
- Author
-
Liu K, Wang F, Wang S, Li WN, and Ye Q
- Subjects
- Animals, Cardiotonic Agents pharmacology, Heme Oxygenase (Decyclizing) genetics, In Vitro Techniques, Male, Mitogen-Activated Protein Kinase 1 genetics, Myocardial Reperfusion Injury metabolism, Myocardial Reperfusion Injury pathology, NF-E2-Related Factor 2 genetics, NF-kappa B genetics, Rats, Rats, Sprague-Dawley, Gene Expression Regulation drug effects, Heme Oxygenase (Decyclizing) metabolism, Mitogen-Activated Protein Kinase 1 metabolism, Myocardial Reperfusion Injury prevention & control, NF-E2-Related Factor 2 metabolism, NF-kappa B metabolism, Xanthones pharmacology
- Abstract
The aim of this study was to investigate the cardioprotective effect of mangiferin (MAF) in vitro and in vivo . Oxidative stress and inflammatory injury were detected in coronary artery ligation in rats and also in hypoxia-reoxygenation- (H/R-) induced H9c2 cells. MAF inhibited myocardial oxidative stress and proinflammatory cytokines in rats with coronary artery occlusion. The ST segment of MAF treatment groups also resumed. Triphenyltetrazolium chloride (TTC) staining and pathological analysis showed that MAF could significantly reduce myocardial injury. In vitro data showed that MAF could improve hypoxia/reoxygenation- (H/R-) induced H9c2 cell activity. In addition, MAF could significantly reduce oxidative stress and inflammatory pathway protein expression in H/R-induced H9c2 cells. This study has clarified the protective effects of MAF on myocardial injury and also confirmed that oxidative stress and inflammation were involved in the myocardial ischemia-reperfusion injury (I/R) model.
- Published
- 2019
- Full Text
- View/download PDF